Annovis Bio, Inc. (ANVS)

↓ Download CSV

CIK 0001477845 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Annovis Bio, Inc. reported revenue of $0. The company ran a net loss. It held $21.08M in total assets against $4.23M in total liabilities.

Key ratios (FY2025)

-171.2%
Return on equity
Metric (FY)20252024202320222021202020192018
Revenue$0$0$0$0$0$0
Operating Income-$29.70M-$26.69M-$45.04M-$25.51M-$14.54M-$6.64M-$1.61M
Net Income-$28.85M-$24.59M-$56.20M-$25.33M-$14.49M-$5.46M-$991.0K
EPS (Diluted)$-1.40$-2.31$-6.23$-3.10$-1.90$-0.87
Total Assets$21.08M$13.93M$10.21M$36.02M$46.00M$8.12M$1.12M
Total Liabilities$4.23M$4.62M$17.96M$7.70M$1.51M$578.4K$2.62M
Shareholders' Equity$16.85M$9.31M-$7.75M$28.32M$44.49M$7.54M-$8.58M-$7.59M
Cash & Equivalents$19.53M$10.55M$5.75M$28.38M$45.69M$8.07M$1.9K
Operating Cash Flow-$25.62M-$21.89M-$39.97M-$17.31M-$9.13M-$3.97M-$476.5K
Shares Outstanding27.20M14.14M10.52M8.16M8.10M6.89M282.6K